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Asymptomatic Clostridium difficile colonization is common in hospitalized patients. Existing C. difficile assay
comparisons lack data on severity of diarrhea or patient outcomes, limiting the ability to interpret their results
in regard to the diagnosis of C. difficile infection (CDI). The objective of this study was to measure how
including patient presentation with the C. difficile assay result impacted assay performance to diagnose CDI.
Stool specimens from 150 patients that met inclusion and exclusion criteria were selected. Nine methods to
detect C. difficile in stool were evaluated. All patients were interviewed prospectively to assess diarrhea severity.
We then assessed how different reference standards, with and without the inclusion of patient presentation,
impact the sensitivity, specificity, and positive and negative predictive values of the assays to diagnose CDI.
There were minimal changes in sensitivity; however, specificity was significantly lower for the assays Tox A/B
II, C. diff Chek-60, BD GeneOhm Cdiff, Xpert C. difficile, and Illumigene C. difficile and for toxigenic culture
(P was <0.01 for all except Tox A/B II from fresh stool, for which the P value was 0.016) when the reference
standard was recovery of toxigenic C. difficile from stool plus the presence of clinically significant diarrhea
compared to when the reference standard was having at least four assays positive while ignoring diarrhea
severity. There were 15 patients whose assay result was reported as negative but subsequently found to be
positive by at least four assays in the comparison. None suffered from any CDI-related adverse events. In
conclusion, clinical presentation is important when interpreting C. difficile diagnostic assays.
Clostridium difficile infection (CDI) is the leading cause of
infectious nosocomial diarrhea in North America and Europe
(3). CDI incidence and severity have been increasing for the
last decade. These changes in CDI epidemiology have brought
renewed focus on methods to detect C. difficile and/or its toxins
in stool.
Because of the lower sensitivity to detect the presence of
toxigenic C. difficile in stool versus other methods, the Society
for Healthcare Epidemiology of America and Infectious Dis-
eases Society of America CDI guidelines state that toxin en-
zyme immunoassays (EIAs) are a suboptimal approach for the
diagnosis of CDI (3). An alternative was not recommended,
leaving laboratory personnel to interpret the C. difficile diag-
nostic literature when choosing a substitute. Although the per-
formance of C. difficile assays relative to each other can be
made, contemporary studies suffer from the use of different
reference standards and inconsistent reporting on the source
and consistency of specimens (23). More importantly, the cur-
rent CDI diagnostic literature does not include prospective
patient interviews to assess clinical symptoms, medication ex-
posures, and/or patient outcomes. CDI is a clinical diagnosis
supported by laboratory or endoscopic evidence, not vice
versa. The lack of clinical data is problematic, because asymp-
tomatic C. difficile colonization and diarrhea are common in
populations exposed to health care facilities (3, 15, 16). It is not
possible to determine the true meaning of a positive C. difficile
assay and how it relates to the diagnosis of CDI in the absence
of patient symptoms and outcomes (14).
In April 2009, the C. difficile toxin EIA used by our institu-
tion became unavailable due to manufacturing difficulties
(ProSpecT Clostridium difficile Toxin A/B; Remel, Lenexa,
KS). A significant drop in CDI incidence was noted when a
replacement toxin EIA was implemented (C. difficile Tox A/B
II; TechLab, Blacksburg, VA). An epidemiological study failed
to identify increased CDI related morbidity or mortality, sug-
gesting the difference was due to improved specificity of the
new assay (7). To confirm this, and because of the limitations
of published studies, a formal assay comparison that included
prospective patient interviews and an assessment of outcomes
was conducted. These data were used to test the hypothesis
that the apparent specificity of any given C. difficile assay for
the diagnosis of CDI will decrease when clinical presentation
of the patient is included in the reference standard.
(These data were presented in part at the 21st Annual Meet-
ing of the Society for Healthcare Epidemiology of America, 1
to 4 April 2011, Dallas, TX.)
MATERIALS AND METHODS
Patient population and stool specimen collection. The study was conducted at
Barnes-Jewish Hospital (BJH), in St. Louis, MO. The BJH microbiology labo-
ratory only tests unformed stools for C. difficile, per published guidelines (3). C.
difficile testing requires an order from a physician for diagnostic purposes. Un-
formed stool, defined as stool that conforms to its container, submitted from
inpatients for C. difficile testing was eligible to be included in the comparison if
it was the first specimen sent during that admission and if a minimum of 10 ml
of stool was submitted. The specimen was tested and results reported per stan-
dard practice with the assay used by the clinical microbiology laboratory during
* Corresponding author. Mailing address: Department of Medicine,
Washington University School of Medicine, 660 S. Euclid, Box 8051,
St. Louis, MO 63110. Phone: (314) 362-8065 Fax: (314) 454-5392.
E-mail: edubberk@dom.wustl.edu.
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the study period (C. difficile Tox A/B II). The remaining specimen was divided
into 10 1-ml aliquots and frozen at 80°C. Patients were interviewed within 24 h
of stool collection. Specimens were excluded if the patient was unable to com-
municate. The first 100 consecutive specimens that met inclusion and exclusion
criteria were included in the study. To better evaluate specificity, an additional 50
specimens that were positive using ProSpecT Clostridium difficile Toxin A/B, the
assay most frequently positive with the first 100 specimens, were collected. The
first 100 specimens were collected between 11 January 2010 and 5 February 2010,
and the last 50 specimens were collected between 19 March 2010 and 30 June
2010.
Patients were interviewed by one of two physicians with infectious diseases
training (E.R.D. or Z.H.). The first 10 interviews were conducted with both
physicians present to standardize the interview process and data collection. The
interviewers were blinded to the assay result reported to the treating physician.
Demographic data, select comorbidities (inflammatory bowel disease and intra-
abdominal surgery in the prior 7 days), and receipt of a laxative in the 48 h prior
to stool specimen collection were recorded. The patients were questioned on the
consistency and number of bowel movements in the 24 h prior to stool collection
and on what was typical for them. Patients selected stool consistency from the
Bristol Stool Chart. Patients rated abdominal pain or cramping on a scale from
1 (no pain/cramping) to 10 (most severe pain/cramping imaginable). An abdom-
inal exam was performed, and the peak temperature and white blood cell count
within 24 h of stool collection were recorded. The outcome at 60 days (death or
recurrent CDI) and empirical CDI treatment for patients whose assay result was
reported as negative but found to be positive in the assay comparison were
assessed.
Testing of stool specimens. The assays compared included two toxin EIAs (C.
difficile Tox A/B II and ProSpecT Clostridium difficile Toxin A/B), one glutamate
dehydrogenase (GDH) EIA (C. diff Chek-60 [TechLab]), and three nucleic acid
amplification tests (BD GeneOhm Cdiff [Becton Dickinson, Franklin Lakes, NJ],
Xpert C. difficile [Cepheid, Sunnyvale, CA], and Illumigene C. difficile [Meridian
Bioscience, Inc., Cincinnati, OH]). All assays were performed according to the
manufacturers’ instructions (the C. difficile Tox A/B II and C. diff Chek-60
package inserts state that activity may be lost if the specimen is frozen, and the
Xpert C. difficile does not state whether specimens can be frozen prior to testing).
Although a positive result from the ProSpecT Clostridium difficile Toxin A/B
from fresh stool was part of the inclusion criteria for the final 50 specimens, the
results of this assay for the fresh specimen were not included in the comparison
because the assay was not performed on the first 100 specimens prior to freezing.
If the initial result of any assay was indeterminate, instructions provided by the
manufacturer to resolve the results of the assay were followed. If repeat results
remained indeterminate, the result recorded for the assay comparison was “neg-
ative.” The person performing the assays was blinded to the results of toxigenic
culture and to the clinical data.
The cytotoxicity cell assay was conducted for all stool specimens. Stool samples
were diluted 1:1 in phosphate-buffered saline to a total volume of 1 ml and
centrifuged for 10 min at 14,000  g. The supernatant was filtered using a sterile
0.45  low-protein-binding syringe filter. The cytotoxicity assay was performed
according to manufacturer’s directions (Clostridium difficile toxin/antitoxin kit;
TechLab). HT-29 adenocarcinoma intestinal cells (HTB 38; American Type
Culture Collection) grown to confluence in 96-well microtiter plates were used.
Samples were tested in duplicate. Cytoxicity was assessed after 24 and 48 h of
incubation in a 37°C CO2 incubator. Samples exhibiting typical cell rounding that
was neutralized with antitoxin were recorded as positive.
Toxigenic culture was performed for all specimens. Stool was incubated with
an equal amount of 95% ethanol (Sigma-Aldrich, St. Louis, MO) at room
temperature for 45 min. The specimen was centrifuged at 2,500  g for 10 min,
and the supernatant was discarded. The pellet was inoculated onto prereduced
cycloserine, cefoxitin, and fructose agar with lysozyme (Anaerobe Systems, Mor-
gan Hill, CA). Plates were inspected for growth after 48 h in an anaerobic
incubator at 35°C. Presumptive C. difficile isolates were identified, by character-
istic colony morphology, smell, and Gram stain, that were also Pro Disk (Remel)
positive and spot indole (Remel) negative (6). All isolates were confirmed to be
C. difficile positive with RapID ANA II (Remel). Any specimen found to be
positive by at least two nonculture methods but not by C. difficile culture was
inoculated into prereduced cycloserine, cefoxitin, and mannitol broth with tau-
rocholate and lysozyme (Anaerobe Systems) (22). If growth was identified within
a week of inoculation, the specimen was subcultured onto prereduced blood agar
(Remel). C. difficile isolates were identified as described above. All C. difficile
isolates were grown in chopped meat broth (Anaerobe Systems) for 48 h. Culture
was tested for cytotoxicity as described above. The presence of the tcdB gene was
assessed by PCR using the primers described by Peterson et al. in nontoxigenic
C. difficile strains recovered from stool for which there was at least one positive
nucleic acid amplification assay result (13).
Statistical analysis. The a priori primary reference standard for the assay
evaluation was a patient with clinically significant diarrhea and toxigenic C.
difficile recovered from stool (standard A) (Table 1) (3). Three alternate refer-
ence standards were also evaluated to determine how different reference stan-
dards impact assay comparisons. These included (i) having the presence of
toxigenic C. difficile while ignoring clinical presentation (standard B), (ii) having
clinically significant diarrhea and at least four assays positive (standard C), and
(iii) having at least four assays positive while ignoring clinical presentation
(standard D). Only results from the frozen specimens were used for the “at least
four assays positive” criteria. Clinically significant diarrhea was defined as at least
three diarrheal bowel movements (type 6 or 7 stool on the Bristol Stool Chart)
in the 24 h preceding stool specimen collection or diarrhea plus patient-reported
abdominal pain or cramping (14). There were four C. difficile isolates that were
nontoxigenic but positive for the tcdB gene. These stool specimens were classi-
fied as negative for toxigenic C. difficile.
Sensitivity and specificity and their 95% confidence intervals were calculated
for each assay against each reference standard. The prevalence for positive and
negative predictive value calculations was based on the results of the respective
reference standard on the first 100 specimens alone. The impact of a two-step
algorithm, i.e., first screening specimens with a GDH EIA (C. diff Chek-60), was
also assessed. The algorithm was positive only if both the GDH and the second
assay were positive. The Wilcoxon rank sum test was used to compare continuous
and ordinal data. Chi-square and Fisher’s exact tests were used for categorical
data. Outcomes of patients whose clinical assay was reported as negative but was
positive by any of the reference standards were described. PASW v17.0 (IBM
SPSS, Inc., Somers, NY) and EpiInfo v6 (CDC, Atlanta, GA) were used for
statistical analysis.
RESULTS
The median age of the 150 patients who met inclusion and
exclusion criteria was 60 years (range, 21 to 96 years) (Table 2).
The race distribution was similar to that typical for BJH (4).
The median peak temperature within 24 h of stool collection
was 37.1°C (range, 35.6°C to 39.7°C), and 27 patients (18%)
had a fever of 38.3°C. Patients had significantly more bowel
movements per day compared to their baseline (median num-
ber of bowel movements was 3 versus 1 at baseline [P 0.001])















A Yes Yes NA Positive
No Yes NA Negative
Yes No NA Negative
No No NA Negative
B Yes Yes NA Positive
No Yes NA Positive
Yes No NA Negative
No No NA Negative
C Yes NA Yes Positive
No NA Yes Negative
Yes NA No Negative
No NA No Negative
D Yes NA Yes Positive
No NA Yes Positive
Yes NA No Negative
No NA No Negative
a The presence of clinically significant diarrhea was ignored when interpreting
the reference standard and the assays being compared for standards B and D.
NA, not applicable.
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and were significantly more likely to have diarrhea compared
to their baseline (median Bristol Stool Chart score was 7 versus
3 at baseline [P  0.001]). Ninety-six patients (64%) met cri-
teria for clinically significant diarrhea. Twenty-eight patients
(19%) received a laxative in the 48 h prior to stool collection.
The results of the assay comparisons for standard A (i.e.,
positive toxigenic culture plus clinically significant diarrhea)
are presented in Table 3. The cytotoxicity cell assay was the
least sensitive (62.9%; 95% confidence interval [CI], 46.3% to
76.8%) in the comparison but was among the most specific
(93.9%; 95% CI, 88.0% to 97.0%). Of the two toxin EIAs in
the comparison, the Tox A/B from fresh stool was the least
sensitive assay (80.0%; 95% CI, 64.1% to 90.0%) and the
ProSpecT was the most sensitive (100%; 95% CI, 90.1% to
100%). Conversely, the most specific toxin EIA was the Tox
A/B from fresh stool (93.9%; 95% CI, 88.0% to 97.0%) and the
least specific was the ProSpecT (67.7%; 95% CI, 59.7% to
76.5%). All nucleic acid amplification tests, along with the
Chek-60 GDH EIA, demonstrated superior sensitivity, but
specificity was 86.1% or lower for these assays. A two-step
algorithm of an initial screen with the Chek-60 GDH EIA
resulted in a significant improvement in specificity for the
ProSpecT (P  0.001).
The prevalence of CDI in the first 100 specimens by standard
A was 11%. The negative predictive value for all assays was
95% (Table 3). The positive predictive values of ProSpecT,
Chek-60, and all three nucleic acid amplification tests were less
than 50%. A GDH screen decreased the number of false positives
for the nucleic acid amplification tests and ProSpecT, but the
positive predictive value increased to above 50% only for the
ProSpecT.
The results of the assay comparisons when the reference
standards were having positive toxigenic culture while ignoring
clinical presentation (standard B), having clinically significant
diarrhea and at least four assays positive (standard C), and
having at least four assays positive while ignoring clinical pre-
sentation (standard D) are provided in Tables 4, 5, and 6,
respectively. The relative rankings of the assays by sensitivity
and specificity within each comparison remain similar. The
sensitivity of toxigenic culture and the ProSpecT relative to
the other assays was lower when the laboratory component of
the reference standard was “at least four assays positive.”
The sensitivity of the assays was unchanged or decreased
TABLE 2. Demographic and clinical dataa
Patient characteristic No. (%) ormedian (range)





Other .......................................................................... 2 (1.4%)
Inflammatory bowel disease ........................................ 13 (8.7%)
Abdominal surgery in previous 7 days....................... 12 (8.0%)
Received laxative in previous 48 h............................. 28 (18.7%)
Time from admission to stool collection (days) ....... 2.9 (0–42.3)
Peak temp within 24 h of stool collection (°C) ........ 37.1 (35.6–39.7)
Peak WBC count within 24 h of stool collection..... 8.8 (0.1–70.0)
Normal no. of bowel movements per day ................. 1 (1–9)
Normal stool consistency (BSC type) ........................ 3 (1–7)
Current no. of bowel movements per day................. 3 (1–20)
Current stool consistency (BSC type)........................ 7 (3–7)
Abdominal pain or cramping ...................................... 1 (1–10)
Hyper- or hypoactive bowel sounds ........................... 28 (18.7%)
Abdominal tenderness ................................................. 53 (35.3%)
Abdominal distention................................................... 20 (13.3%)
Involuntary guarding .................................................... 20 (13.3%)
Rebound tenderness..................................................... 30 (20.0%)
Clinically significant diarrhea...................................... 96 (64%)
a n  150 patients. WBC, white blood cell; BSC, Bristol Stool Chart.




















TechLab Tox A/B fresh 28 108 80.0 (64.1–90.0) 93.9 (88.0–97.0) 61.8 (39.8–78.8) 97.4 (95.2–98.7)
TechLab Tox A/B frozen 33 106 94.3 (81.4–98.4) 92.2 (85.8–95.8) 59.9 (41.5–74.3) 99.2 (97.4–99.8)
Remel ProSpecT frozen 35 79 100 (90.1–100) 67.7 (59.7–76.5) 28.3 (21.7–34.5) 100 (98.0–100)
Cytotoxicity from stool 22 108 62.9 (46.3–76.8) 93.9 (88.0–97.0) 56.0 (32.3–76.0) 95.3 (93.0–97.1)
TechLab Chek 60 35 93 100 (90.1–100) 80.9 (72.7–87.0) 39.3 (29.0–48.7) 100 (98.3–100)
BD GeneOhm 35 97 100 (90.1–100) 84.3 (76.6–89.9) 44.0 (32.2–55.0) 100 (98.4–100)
Cepheid 35 99 100 (90.1–100) 86.1 (78.6–91.3) 47.1 (34.2–58.7) 100 (98.5–100)
Illumigene 34 98 97.1 (85.5–99.5) 85.2 (77.6–90.6) 44.8 (32.1–56.7) 99.6 (97.7–99.9)
Toxigenic culture 35 106 100 (90.1–100) 92.2 (85.8–95.8) 61.3 (44.0–74.6) 100 (98.6–100)
GDH then TechLab Tox A/B frozen 33 106 94.3 (81.4–98.4) 92.2 (85.8–95.8) 59.9 (41.5–74.3) 99.2 (97.4–99.8)
GDH then Remel ProSpecT frozen 35 103 100 (90.1–100) 89.6 (82.6–93.9) 54.3 (39.0–67.0) 100 (98.5–100)
GDH then cytotoxicity from stool 22 109 62.9 (46.3–76.8) 94.8 (89.1–97.6) 59.9 (34.4–79.8) 95.4 (93.1–97.1)
GDH then BD GeneOhm 35 100 100 (90.1–100) 87.0 (79.6–91.9) 48.7 (35.5–60.4) 100 (98.5–100)
GDH then Cepheid 35 100 100 (90.1–100) 87.0 (79.6–91.9) 48.7 (35.3–60.4) 100 (98.5–100)
GDH then Illumigene 34 101 97.1 (85.5–99.5) 87.8 (80.1–92.6) 49.6 (34.7–62.4) 99.6 (97.8–99.9)
GDH then toxigenic culture 35 106 100 (90.1–100) 92.2 (85.8–95.8) 61.3 (44.0–74.6) 100 (98.6–100)
a Shown are assay comparison results with reference standard A (stool samples positive by toxigenic culture plus the presence of clinically significant diarrhea). The
prevalence for positive predictive value (PPV) and negative predictive value (NPV) calculations was 11%. If samples were positive by a screen with glutamate
dehydrogenase EIA (GDH; TechLab Chek-60), the final result was positive only if the second assay was also positive. PPV and NPV estimates were calculated with
the CDI prevalence for the corresponding reference standard and point estimates of sensitivity and specificity. Fresh, assay using fresh stool sample; frozen, assay using
frozen stool sample.
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with the alternate reference standards compared to standard
A. The only significant change was for toxigenic culture when
the reference standard was at having least four positive assays
while ignoring clinical presentation (standard D) (P  0.04).
The specificity and positive predictive values of all of the assays
increased with standards B through D versus those for stan-
dard A. There were trends or significant increases in specificity
when standard B (having toxigenic culture while ignoring clin-
ical presentation) was the reference standard for Tox A/B from
a frozen specimen, the cytotoxicity cell assay, Cepheid (0.1 
P  0.05 for all three), and toxigenic culture (P  0.004).
When the reference standard was having at least four assays
positive while ignoring clinical presentation (standard D),
there were significant increases in specificity for Tox A/B from
fresh and frozen stool, Chek-60, BD GeneOhm, Cepheid, Il-
lumigene, and toxigenic culture (P was0.01 for all except Tox
A/B from fresh stool, for which P was 0.016) compared that to
when standard A was the reference standard.
There were 15 patients whose stool specimen was reported
as negative for C. difficile toxins (Tox A/B from fresh stool) but




















TechLab Tox AB fresh 33 104 75.0 (60.6–85.4) 98.1 (93.4–99.5) 84.3 (55.6–95.9) 96.6 (94.6–98.0)
TechLab Tox AB frozen 39 103 88.6 (76.0–95.1) 97.2 (92.0–99.0) 81.2 (56.2–92.8) 98.4 (96.6–99.3)
Remel ProSpecT frozen 44 79 100 (92.0–100) 74.5 (65.5–81.9) 34.8 (26.7–43.0) 100 (98.4–100)
Cytotoxicity from stool 28 105 63.6 (48.9–76.2) 99.1 (94.9–99.8) 90.6 (56.7–98.1) 95.2 (93.2–96.9)
TechLab Chek 60 44 93 100 (92.0–100) 87.7 (80.1–92.7) 52.6 (38.7–65.1) 100 (98.7–100)
BD GeneOhm 43 96 97.7 (88.2–99.6) 90.6 (83.5–94.8) 58.6 (42.2–72.3) 99.7 (98.1–99.9)
Cepheid 44 99 100 (92.0–100) 93.4 (87.0–96.8) 67.4 (49.1–81.0) 100 (98.8–100)
Illumigene 42 97 95.5 (84.9–98.7) 91.5 (84.7–95.5) 60.5 (43.1–74.9) 99.3 (97.6–99.8)
Toxigenic culture 44 106 100 (92.0–100) 100 (96.5–100) 100 (78.2–100) 100 (98.9–100)
GDH then TechLab Tox AB frozen 39 103 88.6 (76.0–95.1) 97.2 (92.0–99.0) 81.2 (56.4–92.8) 98.4 (96.6–99.3)
GDH then Remel ProSpecT frozen 44 103 100 (92.0–100) 97.2 (92.0–99.0) 83.0 (61.1–93.2) 100 (98.8–100)
GDH then cytotoxicity from stool 28 106 63.6 (48.9–76.2) 100 (96.5–100) 100 (65.6–100) 95.3 (93.3–96.9)
GDH then BD GeneOhm 43 99 97.7 (88.2–99.6) 93.4 (87.0–96.8) 66.9 (48.1–80.9) 99.7 (98.2–99.9)
GDH then Cepheid 44 100 100 (92.0–100) 94.3 (88.2–97.4) 70.5 (51.5–84.0) 100 (98.9–100)
GDH then Illumigene 42 100 95.5 (84.9–98.7) 94.3 (88.2–97.4) 69.6 (49.5–83.8) 99.4 (97.7–99.8)
GDH then toxigenic culture 44 106 100 (92.0–100) 100 (96.5–100) 100 (78.2–100) 100 (98.9–100)
a Shown are assay comparison results with reference standard B (stool samples positive by toxigenic culture only). The prevalence for positive predictive value (PPV)
and negative predictive value (NPV) calculations was 12%. If samples were positive by a screen with glutamate dehydrogenase EIA (GDH; TechLab Chek-60), the final
result was positive only if the second assay was also positive. PPV and NPV estimates were calculated with the CDI prevalence for the corresponding reference standard
and point estimates of sensitivity and specificity. Fresh, assay using fresh stool sample; frozen, assay using frozen stool sample.




















TechLab Tox AB fresh 30 105 75.0 (59.8–85.8) 95.5 (89.8–98.0) 73.1 (48.8–87.5) 95.9 (93.2–97.7)
TechLab Tox AB frozen 36 104 90.0 (77.0–96.0) 94.6 (88.6–97.5) 72.7 (52.4–86.2) 98.3 (95.9–99.3)
Remel ProSpecT frozen 37 76 92.5 (80.1–97.4) 69.1 (59.9–77.0) 32.8 (24.5–40.8) 98.3 (94.9–99.5)
Cytotoxicity from stool 22 103 55.0 (39.8–69.3) 93.6 (87.4–96.9) 58.3 (34.0–78.4) 92.7 (89.9–95.1)
TechLab Chek 60 40 93 100 (91.2–100) 84.6 (76.6–90.1) 51.2 (38.8–62.2) 100 (98.2–100)
BD GeneOhm 40 97 100 (91.2–100) 88.2 (80.8–93.0) 58.0 (43.6–69.9) 100 (98.3–100)
Cepheid 40 99 100 (91.2–100) 90.0 (83.0–94.3) 61.9 (46.6–74.1) 100 (98.3–100)
Illumigene 39 98 97.5 (87.1–99.6) 89.1 (81.9–93.7) 59.3 (43.9–72.0) 99.5 (97.5–99.9)
Toxigenic culture 35 101 87.5 (73.9–94.5) 91.8 (85.2–95.6) 63.5 (44.8–77.8) 97.8 (95.2–99.1)
GDH then TechLab Tox AB frozen 36 104 90.0 (77.0–96.0) 94.6 (88.6–97.5) 72.7 (52.4–86.2) 98.3 (95.9–99.3)
GDH then Remel ProSpecT frozen 37 100 92.5 (80.1–97.4) 90.9 (84.1–95.0) 62.3 (45.1–76.0) 98.7 (96.3–99.6)
GDH then cytotoxicity from stool 22 104 55.0 (39.8–69.3) 94.6 (88.6–97.5) 61.9 (36.2–81.9) 92.8 (90.0–95.1)
GDH then BD GeneOhm 40 100 100 (91.2–100) 90.9 (84.1–95.0) 64.1 (48.3–76.5) 100 (98.3–100)
GDH then Cepheid 40 100 100 (91.2–100) 90.9 (84.1–95.0) 64.1 (48.3–76.5) 100 (98.3–100)
GDH then Illumigene 39 101 97.5 (87.1–99.6) 91.8 (85.2–95.6) 65.9 (48.9–78.7) 99.6 (97.6–99.9)
GDH then toxigenic culture 35 101 87.5 (73.9–94.5) 91.8 (85.2–95.6) 63.5 (44.8–77.8) 97.8 (95.2–99.1)
a Shown are assay comparison results with reference standard C (stool samples positive by at least four assays from frozen specimens plus the presence of clinically
significant diarrhea). The prevalence for positive predictive value (PPV) and negative predictive value (NPV) calculations was 14%. If samples were positive by a screen
with glutamate dehydrogenase EIA (GDH; TechLab Chek-60), the final result was positive only if the second assay was also positive. PPV and NPV estimates were
calculated with the CDI prevalence for the corresponding reference standard and point estimates of sensitivity and specificity. Fresh, assay using fresh stool sample;
frozen, assay using frozen stool sample.
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was positive by at least four assays (Table 7). Eleven (73.3%)
of these patients were positive by toxigenic culture, and three
(20%) were positive by the cytotoxicity cell assay. Ten (66.7%)
had clinically significant diarrhea. Five (33.3%) of the patients
whose Tox A/B result from fresh stool was discordant with the
“at least four assays positive” criteria received a laxative in the
48 h prior to stool specimen collection compared to 23 patients
(17.0%) whose Tox A/B result from fresh stool was concordant
(P  0.16). Four patients (26.7%) received empirical treat-
ment for CDI. Three patients died from reasons unrelated to
CDI. None of the 15 patients were subsequently diagnosed
with CDI.
DISCUSSION
The C. difficile diagnostic assay literature suffers from use of
different reference standards, inconsistent reporting of stool
collection criteria, and most importantly, a lack of data on
severity of diarrhea and CDI-related outcomes. Asymptomatic
C. difficile colonization is common in patient populations that
are tested for C. difficile (3, 16). Therefore, data on the pa-
tient’s clinical presentation are needed for accurate interpre-
tation of assay results for the diagnosis of CDI (3, 14). To our
knowledge, there is only one other C. difficile assay comparison
in the literature that included a prospective patient evaluation
of patients who had stools submitted for C. difficile testing
based on orders from a treating clinician (13). Peterson et al.
found the sensitivity, specificity, and positive and negative pre-
dictive values of their in-house nucleic acid amplification test
to be 93.3%, 97.4%, 75.7%, and 99.4%, respectively. Thirty-
nine percent of patients did not meet their criteria for clinically
significant diarrhea, similar to the 36% in this study. However,
they excluded the stools from these patients in their compar-
ison. This likely biased the specificity of the assays in their
comparison to be higher than if these patients were not ex-
cluded. Therefore, our study, by including patients whose
treating clinicians ordered a test for C. difficile but who did not
have clinically significant diarrhea, is more generalizable to the
population of hospitalized patients being tested for C. difficile.
The results of this study support the hypothesis that including
clinical presentation in the reference standard will decrease
the specificity of C. difficile assays for the diagnosis of CDI.
Although limited by small sample size, the outcome data col-
lected support this hypothesis, i.e., there were no CDI-related




















TechLab Tox AB fresh 35 100 70.0 (56.3–80.1) 100 (96.3–100) 100 (74.3–100) 94.6 (92.0–96.3)
TechLab Tox AB frozen 42 100 84.0 (71.5–91.7) 100 (96.3–100) 100 (78.6–100) 97.0 (94.7–98.4)
Remel ProSpecT frozen 47 76 94.0 (83.8–97.9) 76.0 (66.8–83.3) 42.7 (32.5–52.8) 98.5 (95.6–99.5)
Cytotoxicity from stool 28 99 56.0 (42.3–68.8) 99.0 (94.6–99.8) 91.4 (59.9–98.5) 92.2 (89.6–94.4)
TechLab Chek 60 50 93 100 (92.9–100) 93.0 (86.3–96.6) 73.1 (56.4–84.9) 100 (98.5–100)
BD GeneOhm 49 96 98.0 (89.5–99.7) 96.0 (90.2–98.4) 82.4 (63.5–92.2) 99.6 (97.8–99.9)
Cepheid 49 98 98.0 (89.5–99.7) 98.0 (93.0–99.5) 90.3 (70.9–97.4) 99.6 (97.9–99.9)
Illumigene 48 97 96.0 (86.5–98.9) 97.0 (91.6–99.0) 85.9 (66.2–95.0) 99.2 (97.3–99.8)
Toxigenic culture 44 100 88.0 (76.2–94.4) 100 (96.3–100) 100 (79.7–100) 97.8 (95.5–98.9)
GDH then TechLab Tox AB frozen 42 100 84.0 (71.5–91.7) 100 (96.3–100) 100 (78.6–100) 97.0 (94.7–98.4)
GDH then Remel ProSpecT frozen 47 100 94.0 (83.8–97.9) 100 (96.3–100) 100 (81.2–100) 98.9 (96.9–99.6)
GDH then cytotoxicity from stool 28 100 56.0 (42.3–68.8) 100 (96.3–100) 100 (68.5–100) 92.3 (89.9–94.4)
GDH then BD GeneOhm 49 99 98.0 (89.5–99.7) 99.0 (94.6–99.8) 94.9 (75.9–99.0) 99.6 (97.9–99.9)
GDH then Cepheid 49 99 98.0 (89.5–99.7) 99.0 (94.6–99.8) 94.9 (75.9–99.0) 99.6 (97.9–99.9)
GDH then Illumigene 48 100 96.0 (86.5–98.9) 100 (96.3–100) 100 (81.7–100) 99.2 (97.4–99.8)
GDH then toxigenic culture 44 100 88.0 (76.2–94.4) 100 (96.3–100) 100 (79.7–100) 97.8 (95.5–98.9)
a Shown are assay comparison results with reference standard D (stool samples positive by at least four assays only). The prevalence for positive predictive value
(PPV) and negative predictive value (NPV) calculations was 16%. If samples were positive by a screen with glutamate dehydrogenase EIA (GDH; TechLab Chek-60),
the final result was positive only if the second assay was also positive. PPV and NPV estimates were calculated with the CDI prevalence for the corresponding reference
standard and point estimates of sensitivity and specificity. Fresh, assay using fresh stool sample; frozen, assay using frozen stool sample.
TABLE 7. Treatment and outcomes of patients whose C. difficile
test was reported as negative by Techlab Tox A/B from fresh


















15a Yes Yes No No No
21a Yes No Metronidazole Yesd No
25 No No No No No
35b Yes Yes No No No
54b Yes No No Yese No
70b Yes Yes No No No
82a,c Yes No Metronidazole No No
109a No No No No No
112a No No No No No
113a,c Yes No No No No
118a,c No No No No No
122a Yes No Vancomycin No No
126a No Yes Metronidazole No No
148a Yes No No No No
149a Yes Yes No Yesf No
a Toxigenic C. difficile isolated from stool.
b Nontoxigenic C. difficile isolated from stool.
c Cytotoxicity cell assay of stool was positive.
d Patient died from ischemic cardiomyopathy.
e Patient died from respiratory failure secondary to metastatic carcinoma.
f Patient died from pneumonia.
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adverse events in the patients whose assay result was reported
as negative (C. difficile Tox A/B II from fresh stool) but found
to be positive by other assays.
When clinical criteria were included in the reference stan-
dard, the positive predictive value of some assays decreased
such that there would be as many, if not more, false positives
as true positives (Tables 3 through 6). While it is important to
accurately diagnose true cases of CDI to avoid delays in treat-
ment and the risk of disease progression, there are likely costs
due to false-positive results as well. In one placebo-controlled
study of treating asymptomatic C. difficile carriers, the only
patient to develop CDI after treatment was stopped had re-
ceived oral vancomycin (8). Other potential costs include di-
rect and indirect costs of placing patients under contact pre-
cautions when not otherwise indicated, decreases in patient
satisfaction, and increases in adverse events associated with
contact precautions (10, 17, 21). Increases in CDI incidence
due to false-positive assays will also divert limited infection
prevention and control resources and lead to false impressions
if CDI rates are reported to the public.
The appropriate reference standard when comparing C. dif-
ficile assays is not clear. The Society for Healthcare Epidemi-
ology of America and Infectious Diseases Society of America
guidelines recommend toxigenic culture as the gold standard
laboratory comparator (B-III recommendation) (3). Toxigenic
C. difficile was not isolated from six specimens that were pos-
itive by at least four assays in this study. C. difficile was cultured
from five of these specimens, but cytotoxicity was not detected
from culture. These patients may have had more than one
strain of C. difficile present, and the isolates selected to assess
toxin production were nontoxigenic. Interestingly, four of these
strains were positive for the tcdB toxin B gene. The optimal
methods for detecting toxin production from culture have not
been defined (15, 19). It is possible that our method of per-
forming the cytotoxicity cell assay was not sufficiently sensitive
to detect toxin production. Because of the discordance be-
tween cytotoxicity testing and the presence of the tcdB gene,
cytotoxicity testing of these isolates was repeated with Vero
cells, and the incubation period was extended to 96 h for both
cell lines. Cytotoxicity was still not identified. Two of these
patients had a negative Tox A/B result for fresh specimen and
were never treated for CDI (Table 7, subjects 35 and 70).
Subject 70 also had a colonoscopy, which was normal. The
other two patients had other potential explanations for diar-
rhea and had a very protracted improvement in symptoms after
CDI treatment was started, suggesting that the diarrhea was
not due solely to CDI. These unique strains are being further
characterized, by methods including whole-genome sequenc-
ing, to determine if the lack of cytotoxicity is due to a decrease
in toxin production or production of nonfunctional toxin.
Some investigators feel that toxigenic culture is too sensitive
and may detect asymptomatic carriage in patients with diar-
rhea for other reasons and that the cytotoxicity cell assay is the
most appropriate reference standard for identifying patients
with CDI because it detects biologically active toxin (15). No-
tably, the cytotoxicity cell assay was the least sensitive method
in this study. This may be due to degradation of toxin in the
specimen during transport or upon prolonged storage or meth-
odological problems with the assay. However, the assay was
performed using methods previously described by an investi-
gator experienced in the technique (2). The performance of
the assay may be related to poor patient selection for C. difficile
testing. Conversely, the 95% confidence interval of the cyto-
toxicity cell assay overlaps with the 95% confidence intervals of
the Tox A/B and was within the ranges of reported sensitivities
in the literature (3, 22). It may have been the least sensitive
assay in this study by chance as well (22).
Some C. difficile assay comparisons use a nontoxigenic cul-
ture, noncytotoxicity cell assay reference standard, or compos-
ite endpoint where true positives are specimens that are pos-
itive by multiple assays (9, 11, 13, 18). Due to the difficulties of
performing toxigenic culture and the cytotoxicity cell assay, this
is frequently the reference standard that clinical laboratories
use when conducting assay comparisons and, hence, the reason
a composite laboratory standard was assessed here. There are
potential problems with this approach. The reference standard
is a surrogate for the desired endpoint (toxigenic C. difficile or
the presence of active toxin in stool). In addition, as demon-
strated in this study, a composite endpoint biases the results
toward improved sensitivity and specificity of the assays in-
cluded in the composite endpoint.
There were other interesting findings in this study. Although
the Techlab assays warn of a possible decrease in sensitivity
with freezing, the Tox A/B from the frozen specimen was more
sensitive than that from the fresh specimen, and the Chek-60
had 100% sensitivity. The Tox A/B from the frozen specimen
was performed by a single experienced medical technologist as
a part of this study. The Tox A/B from the fresh sample was
performed as part of a constellation of duties by a technologist
on the third shift. Other studies do indicate there may be
variability in toxin EIA sensitivities across laboratories (5, 12,
22). This may be due to operator variability. Notably, almost
20% of patients were on a laxative. This is indicative of poor
patient selection for C. difficile testing and may have impacted
our findings. The least specific assay was the ProSpecT. This
was consistent with the results of the epidemiological investi-
gation that was performed when a dramatic drop in CDI inci-
dence was noted after the assay at our institution was changed
to the Tox A/B (7).
This study demonstrates the importance of clinical informa-
tion when interpreting C. difficile assay results. The high pro-
portion of patients without clinically significant diarrhea and
the number of patients on laxatives indicate that we need
validated criteria for when to test for C. difficile. Another
potential area of study is validation of inflammatory biomark-
ers to help determine when detection of toxigenic C. difficile
from stool is clinically significant (1, 20). Finally, there is an
urgent need for C. difficile assay comparison studies that are
adequately powered to assess patient outcomes. Although
there has been great enthusiasm in the literature and the clin-
ical microbiology community regarding the use of molecular
diagnostics for the diagnosis of CDI, the optimal method for
diagnosing CDI will remain elusive until these issues are re-
solved.
ACKNOWLEDGMENTS
This work was supported by grants from the Centers for Disease
Control and Prevention (5U01C1000333) and National Institute of
Allergy and Infectious Diseases (K23AI065806, T32AI007172).




arch 8, 2014 by W






We acknowledge and appreciate the editorial assistance of Kimberly
A. Reske in the preparation of the manuscript.
E.R.D. has performed research for Optimer and Merck and is a
consultant for Optimer, Merck, Pfizer, Becton-Dickinson, Meridian,
and Steris. C.-A.D.B. has received speaker honoraria for Meridian and
is a consultant for Quidel, BioMerieux, and Luminex. Z.H., L.B., T.H.,
B.L., S.C., J.H.-B., and W.M.D. have no disclosures.
REFERENCES
1. Bobo, L., E. R. Dubberke, P. Tarr, and D. Haslam. 2010. Fecal activated
protein kinase 2 elevation is significantly associated with human Clostridium
difficile infection, abstr. 1415. Abstr. 48th Annu. Meet. Infect. Dis. Soc. Am.
Infectious Diseases Society of America, Arlington, VA.
2. Chang, T. W., S. L. Gorbach, and J. B. Bartlett. 1978. Neutralization of
Clostridium difficile toxin by Clostridium sordellii antitoxins. Infect. Immun.
22:418–422.
3. Cohen, S. H., et al. 2010. Clinical practice guidelines for Clostridium difficile
infection in adults: 2010 update by the Society for Healthcare Epidemiology
of America (SHEA) and the Infectious Diseases Society of America (IDSA).
Infect. Control Hosp. Epidemiol. 31:431–455.
4. Dubberke, E. R., et al. 2007. Clostridium difficile-associated disease in a
setting of endemicity: identification of novel risk factors. Clin. Infect. Dis.
45:1543–1549.
5. Eastwood, K., P. Else, A. Charlett, and M. Wilcox. 2009. Comparison of nine
commercially available Clostridium difficile toxin detection assays, a real-
time PCR assay for C. difficile tcdB, and a glutamate dehydrogenase detec-
tion assay to cytotoxin testing and cytotoxigenic culture methods. J. Clin.
Microbiol. 47:3211–3217.
6. Fedorko, D. P., and E. C. Williams. 1997. Use of cycloserine-cefoxitin-
fructose agar and L-proline-aminopeptidase (PRO Discs) in the rapid iden-
tification of Clostridium difficile. J. Clin. Microbiol. 35:1258–1259.
7. Han, Z., K. McMullen, S. M. Copper, D. K. Warren, and E. R. Dubberke. A
Clostridium difficile infection “intervention:” change in toxin assay results in
lower number of C. difficile infection cases without changes in patient out-
comes. Am. J. Infect. Control, in press.
8. Johnson, S., et al. 1992. Treatment of asymptomatic Clostridium difficile
carriers (fecal excretors) with vancomycin or metronidazole: a randomized,
placebo-controlled trial. Ann. Intern. Med. 117:297–302.
9. Karre, T., L. Sloan, R. Patel, J. Mandrekar, and J. Rosenblatt. 2011. Com-
parison of two commercial molecular assays to a laboratory-developed mo-
lecular assay for diagnosis of Clostridium difficile infection. J. Clin. Micro-
biol. 49:725–727.
10. Kirkland, K. B., and J. M. Weinstein. 1999. Adverse effects of contact
isolation. Lancet 354:1177–1178.
11. Kvach, E. J., D. Ferguson, P. F. Riska, and M. L. Landry. 2010. Comparison
of BD GeneOhm Cdiff real-time PCR assay with a two-step algorithm and a
toxin A/B enzyme-linked immunosorbent assay for diagnosis of toxigenic
Clostridium difficile infection. J. Clin. Microbiol. 48:109–114.
12. Novak-Weekley, S. M., et al. 2010. Clostridium difficile testing in the clinical
laboratory by use of multiple testing algorithms. J. Clin. Microbiol. 48:889–
893.
13. Peterson, L. R., et al. 2007. Detection of toxigenic Clostridium difficile in
stool samples by real-time PCR for the diagnosis of C. difficile-associated
diarrhea. Clin. Infect. Dis. 45:1152–1160.
14. Peterson, L. R., and A. Robicsek. 2009. Does my patient have Clostridium
difficile infection? Ann. Intern. Med. 151:176–179.
15. Planche, T., and M. Wilcox. 2011. Reference assays for Clostridium difficile
infection: one or two gold standards? J. Clin. Pathol. 64:1–5.
16. Riggs, M. M., et al. 2007. Asymptomatic carriers are a potential source for
transmission of epidemic and nonepidemic Clostridium difficile strains
among long-term care facility residents. Clin. Infect. Dis. 45:992–998.
17. Saint, S., L. A. Higgins, B. K. Nallamothu, and C. Chenoweth. 2003. Do
physicians examine patients in contact isolation less frequently? A brief
report. Am. J. Infect. Control 31:354–356.
18. Samra, Z., A. Luzon, and J. Bishara. 2008. Evaluation of two rapid immu-
nochromatography tests for the detection of Clostridium difficile toxins. Dig.
Dis. Sci. 53:1876–1879.
19. She, R. C., R. J. Durrant, and C. A. Petti. 2009. Evaluation of enzyme
immunoassays to detect Clostridium difficile toxin from anaerobic stool
culture. Am. J. Clin. Pathol. 131:81–84.
20. Steiner, T. S., C. A. Flores, T. T. Pizarro, and R. L. Guerrant. 1997. Fecal
lactoferrin, interleukin-1beta, and interleukin-8 are elevated in patients with
severe Clostridium difficile colitis. Clin. Diagn. Lab. Immunol. 4:719–722.
21. Stelfox, H. T., D. W. Bates, and D. A. Redelmeier. 2003. Safety of patients
isolated for infection control. JAMA 290:1899–1905.
22. Tenover, F. C., et al. 2010. Impact of strain type on detection of toxigenic
Clostridium difficile: comparison of molecular diagnostic and enzyme immu-
noassay approaches. J. Clin. Microbiol. 48:3719–3724.
23. Wilcox, M. H., T. Planche, F. C. Fang, and P. Gilligan. 2010. What is the
current role of algorithmic approaches for diagnosis of Clostridium difficile
infection? J. Clin. Microbiol. 48:4347–4353.




arch 8, 2014 by W
ashington University in St. Louis
http://jcm.asm.org/
D
ow
nloaded from
 
